By: D. Selleslag MD
The ASH 2018 conference in San Diego featured a number of exciting new studies with clinical relevance for the treatment of patients with acute myeloid leukemia (AML). The key studies that are discussed here are grouped in 3 broad treatment groups: targeted therapies, immunotherapy and allogeneic stem cell transplantation (allo SCT).
(BELG J HEMATOL 2019;10(1):36–40)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
